OncoMatch/Clinical Trials/NCT07189455

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Is NCT07189455 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including ZG006 and Topotecan for small-cell lung cancer.

Phase 3RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdNCT07189455Data as of Jun 2026Location: China

Treatment: ZG006 · Topotecan — The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

Topotecan

Other

ZG006

Cancer type

Small Cell Lung Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07189455 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Small Cell Lung Cancer trials